Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ2G69)

• Drug Name: Navicixizumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Phase 1	[1]
Fallopian tube cancer	2C74	Phase 1	[2]
Metastatic colorectal cancer	2B91	Phase 1	[2]
Ovarian cancer	2C73	Phase 1	[1]
Peritoneal cavity cancer	2C51.Z	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMZ2G69

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor A (VEGFA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[3]
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[4]
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[5]
Ranibizumab	DMSYPNW	Central retinal vein occlusion with macular edema		Approved	[6]
Bevacizumab	DMSD1UN	Adenocarcinoma	2D40	Approved	[7]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[8]
PTC299	DMP9TKE	Rheumatoid arthritis	FA20	Phase 2	[9]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[10]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[11]
Abicipar pegol	DM59OJ2	Diabetic macular edema	9B71.02	Phase 2	[12]

Drug(s) Targeting Delta-like protein 4 (DLL4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dilpacimab	DMCATH2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
ABT-165	DMQ3O1U	Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]
NOV1501	DME2QUZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
REGN-421	DMWJ0IH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
OMP-21M18	DMX1D0S	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Delta-like protein 4 (DLL4)	TTV23LH	DLL4_HUMAN	Not Available	[1]
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Not Available	[1]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [6] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
• [7] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [8] Clinical pipeline report, company report or official report of Genentech (2009).
• [9] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
• [10] Bispecific antibodies and their applications
• [11] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
• [14] Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Rep. 2020 Nov;53(10):533-538.
• [15] J Clin Oncol 31, 2013 (suppl; abstr 2502).
• [16] National Cancer Institute Drug Dictionary (drug id 614677).